Kymera Therapeutics Files Q1 2025 10-Q
Ticker: KYMR · Form: 10-Q · Filed: May 9, 2025 · CIK: 1815442
| Field | Detail |
|---|---|
| Company | Kymera Therapeutics, Inc. (KYMR) |
| Form Type | 10-Q |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, public-offering, biotech
Related Tickers: SNY
TL;DR
Kymera Q1 2025 10-Q filed. Shows cash, debt, and recent stock offerings. #biotech
AI Summary
Kymera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position, including assets like U.S. Treasury Securities and liabilities related to facility leases. Key events mentioned include a follow-on public offering on January 9, 2024, and a Jefferies Sales Agreement for common stock as of October 31, 2024.
Why It Matters
This filing provides investors with an update on Kymera Therapeutics' financial health and operational activities for the first quarter of 2025, including details on recent stock offerings.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development and regulatory hurdles.
Key Numbers
- N/A — Total Assets (Specific asset values not detailed in the provided snippet.)
- N/A — Total Liabilities (Specific liability values not detailed in the provided snippet.)
- N/A — Revenue (Revenue figures not detailed in the provided snippet.)
Key Players & Entities
- Kymera Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- January 9, 2024 (date) — Date of a follow-on public offering
- October 31, 2024 (date) — Date related to Jefferies Sales Agreement for common stock
- U.S. Treasury Securities (dollar_amount) — Asset reported
FAQ
What was the nature of the "TwoThousandTwentyFourFollowOnPublicOfferingMember" that occurred on January 9, 2024?
The filing indicates a follow-on public offering occurred on January 9, 2024, involving "PreFundedWarrantsMember" and the "TwoThousandTwentyFourFollowOnPublicOfferingMember".
What is the context of "UnbilledReceivablesSanofiMember" as of March 31, 2025?
The filing mentions "UnbilledReceivablesSanofiMember" in relation to the reporting period ending March 31, 2025, suggesting a receivable from Sanofi.
What type of financial instruments are associated with the "JefferiesSalesAgreementOrJefferiesLlcMember" on October 31, 2024?
The filing links the "JefferiesSalesAgreementOrJefferiesLlcMember" with "CommonStockMember" as of October 31, 2024.
What is the significance of "kymr:WatertownMassachusettsMember" in the filing?
This entity likely refers to the company's location in Watertown, Massachusetts, as indicated by the business address details.
What does the "kymr:NoncancelableFacilityLeaseAgreementMember" from October 2019 pertain to?
This refers to a non-cancelable facility lease agreement entered into around October 2019, details of which would be further elaborated within the full filing.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 9, 2025 regarding Kymera Therapeutics, Inc. (KYMR).